Survodutide, an experimental once-weekly injection from Boehringer Ingelheim that acts on both the GLP-1 and glucagon receptors, reduced body weight by 8.2% to 9.8% over 76 weeks in adults with obesity and type 2 diabetes, against 3.9% on placebo, in a phase 3 trial published in the New England Journal of Medicine on 1 October. … Read more
When a state Medicaid programme starts paying for GLP-1 drugs labeled for obesity, the bill for those drugs goes up. A study in JAMA Health Forum suggests the net increase is smaller than that figure implies, because some of the new obesity-labeled prescriptions appear to replace diabetes-labeled versions of the same molecules, which every state … Read more
A review of 34 randomised trials in PLoS Medicine has tested the standard first-line advice for polyendocrine metabolic ovarian syndrome (PMOS) — the condition long called polycystic ovary syndrome, or PCOS, recently renamed by an international consensus. Structured diet, exercise and behavioural programmes improved fasting insulin, and made regular menstrual cycles more likely, compared with … Read more
Two analyses of the SELECT trial, published a day apart, reach the same uncomfortable conclusion from different directions. The first, in the European Heart Journal, tried to work out how much of semaglutide’s 20% reduction in heart attacks, strokes and cardiovascular deaths runs through weight loss and the other risk factors it improves, and could … Read more
Adults with obesity and a raised inflammatory marker who were prescribed a GLP-1 receptor agonist had fewer deaths, heart attacks and strokes over the following decade than closely matched adults given an older weight or diabetes drug, according to a study published on 21 September in the American Journal of Cardiology. The gap was driven … Read more
Ultra-processed foods are associated with higher rates of seven major health outcomes, obesity and overweight among them, according to a dose-response meta-analysis of 51 prospective cohort studies covering 8,819,894 adults, published on 22 September 2026 in Family Medicine and Community Health. People in the highest intake groups had a 23% higher rate of obesity or … Read more
Prescriptions for GLP-1 receptor agonists written to US adults with no documented reason for taking them rose roughly 15-fold between 2021 and 2025, according to an analysis of electronic health records published on 22 September in Obesity. Among 92.4 million adults whose records showed neither type 2 diabetes nor obesity with a qualifying comorbidity, about … Read more
Novo Nordisk announced this morning that CagriSema, its investigational combination of semaglutide and a second hormone, beat tirzepatide on weight loss in a head-to-head phase 3 trial in adults with type 2 diabetes: an estimated 12.4% against 9.1% at week 60. A second phase 3 trial put CagriSema at 21.0% weight loss against 2.0% on … Read more